{
    "clinical_study": {
        "@rank": "63875", 
        "arm_group": {
            "arm_group_label": "Lanreotide", 
            "arm_group_type": "Experimental", 
            "description": "Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)"
        }, 
        "brief_summary": {
            "textblock": "Somatostatine induces a dose-dependent reduction of postprandial plasma cholecystokinin\n      (CCK) secretion with a concomitant inhibition of postprandial gallbladder contraction,\n      abolishing almost completely bile salts output from the gallbladder.  Somatostatine is also\n      known to decrease acid production with significant increase of intragastric pH.  In this\n      way, somatostatine could influence acid as well as non-acid reflux by decreasing gallbladder\n      emptying and decreasing acid secretion.\n\n      Purpose of the study is to evaluate the efficacy of lanreotide autogel 120 mg on symptoms\n      and endoscopic lesions in patients with an endoscopic gastrointestinal reflux esophagitis\n      that cannot be controlled with classic therapy."
        }, 
        "brief_title": "Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acid Reflux Esophagitis", 
            "Non-acid Reflux Esophagitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bile Reflux", 
                "Esophagitis", 
                "Esophagitis, Peptic", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients presenting with persistent esophagitis on endoscopy while on proton pump inhibitors\n      (PPI) treatment will receive a maximal therapy consisting of 2 x 40 mg of PPI before the\n      meals (morning and evening) and a H2 blocker before bedtime (standard practice).  They will\n      be reevaluated endoscopically and clinically 2 months later (standard practice).  If reflux\n      persists, objectivized by impedancemetry (standard practice), they will be asked to\n      participate in this study.\n\n      Lanreotide autogel 120 mg deep subcutaneously every 4 weeks will be added to the treatment.\n      A total of 3 injections per patient have been foreseen in this proof of concept study.\n\n      Patients will be reevaluated clinically after 2, 4 and 8 weeks.  At the end of the study a\n      new upper gastrointestinal endoscopy and impedancemetry will be performed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg\n             (before breakfast and dinner) and 300 mg of H2 blocker ranitidine (at bedtime).\n\n        The Los Angeles classification (LA) will be used to evaluate endoscopic reflux.  Any\n        distal esophageal ulcer with negative biopsy is also diagnostic for reflux.\n\n        Persistent reflux is defined as:\n\n        No reflux complaints but continuing endoscopic lesions and positive impedancemetry.\n\n        Reflux complaints with continuing endoscopic lesions and positive impedancemetry.\n\n        Reflux complaints without endoscopic lesions but positive impedancemetry.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or inadequate anticonception, breast feeding.\n\n          -  Negative impedancemetry.\n\n          -  Diabetes.\n\n          -  Placement of a gastric ring for weight loss."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054637", 
            "org_study_id": "PHV106-B.05"
        }, 
        "intervention": {
            "arm_group_label": "Lanreotide", 
            "intervention_name": "Lanreotide", 
            "intervention_type": "Drug", 
            "other_name": "Somatuline"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lanreotide", 
                "Angiopeptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bile reflux", 
            "Reflux esophagitis", 
            "Lanreotide autogel", 
            "Somatuline", 
            "Endoscopy", 
            "Impedancemetry"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "kimmoubax970@hotmail.com/kim.moubax@uzbrussel.be", 
                "last_name": "Kim Moubax, Assistent", 
                "phone": "003224749346", 
                "phone_ext": "0032476486103"
            }, 
            "contact_backup": {
                "email": "daniel.urbain@uzbrussel.be", 
                "last_name": "Dani\u00ebl Urbain, Professor"
            }, 
            "facility": {
                "address": {
                    "city": "Jette", 
                    "country": "Belgium", 
                    "zip": "1090"
                }, 
                "name": "University Hospital of Brussels"
            }, 
            "investigator": {
                "last_name": "kim moubax, assistent", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy", 
        "overall_contact": {
            "email": "kimmoubax970@hotmail.com/kim.moubax@uzbrussel.be", 
            "last_name": "Kim Moubax, Assistent", 
            "phone": "003224749346", 
            "phone_ext": "0032476486103"
        }, 
        "overall_contact_backup": {
            "email": "daniel.urbain@uzbrussel.be", 
            "last_name": "Dani\u00ebl Urbain, Professor"
        }, 
        "overall_official": {
            "affiliation": "University hospital of Brussels, Laarbeeklaan, Jette", 
            "last_name": "Kim Moubax, Assistent", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Endoscopy at the start of the study will be compared with endoscopy at the end of the study.", 
            "measure": "Los Angeles criteria for reflux esophagitis", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after the last injection with lanreotide"
        }, 
        "reference": [
            {
                "PMID": "16240061", 
                "citation": "Ishikawa M, Kitayama J, Kaizaki S, Nakayama H, Ishigami H, Fujii S, Suzuki H, Inoue T, Sako A, Asakage M, Yamashita H, Hatono K, Nagawa H. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg. 2005 Nov;29(11):1415-20; discussion 1421."
            }, 
            {
                "PMID": "12239969", 
                "citation": "Montesani C, D'Amato A, Santella S, Pronio A, Giovannini C, Cristaldi M, Ribotta G. Billroth I versus Billroth II versus Roux-en-Y after subtotal gastrectomy. Prospective [correction of prespective] randomized study. Hepatogastroenterology. 2002 Sep-Oct;49(47):1469-73."
            }, 
            {
                "PMID": "17314604", 
                "citation": "Gerard PS, Gerczuk P, Finestone H. Bile reflux in the esophagus demonstrated by HIDA scintigraphy. Clin Nucl Med. 2007 Mar;32(3):224-5."
            }, 
            {
                "PMID": "19095503", 
                "citation": "Swartz DE, Mobley E, Felix EL. Bile reflux after Roux-en-Y gastric bypass: an unrecognized cause of postoperative pain. Surg Obes Relat Dis. 2009 Jan-Feb;5(1):27-30. doi: 10.1016/j.soard.2008.10.009. Epub 2008 Oct 30."
            }, 
            {
                "PMID": "22430616", 
                "citation": "Gans SL, van Westreenen HL, Kiewiet JJ, Rauws EA, Gouma DJ, Boermeester MA. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg. 2012 Jun;99(6):754-60. doi: 10.1002/bjs.8709. Epub 2012 Mar 20. Review."
            }, 
            {
                "PMID": "10223779", 
                "citation": "Drewe J, Sieber CC, Mottet C, Wullschleger C, Larsen F, Beglinger C. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. Clin Pharmacol Ther. 1999 Apr;65(4):413-9."
            }, 
            {
                "PMID": "9056054", 
                "citation": "Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol. 1997 Jan;43(1):65-70."
            }, 
            {
                "PMID": "21964965", 
                "citation": "Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011 Oct;28(10):825-41. doi: 10.1007/s12325-011-0062-9. Epub 2011 Sep 28. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054637"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitair Ziekenhuis Brussel", 
            "investigator_full_name": "Kim Moubax", 
            "investigator_title": "Dr. Kim Moubax, gastro-enterology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universitair Ziekenhuis Brussel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitair Ziekenhuis Brussel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}